Through the survival analysis of galectin-1 expression, its value as a prognostic factor has been established in prostate, ovarian, and stomach cancers, and high galectin-1 expression has been correlated with poor prognosis [21,40,41]. This evidence concerns the gene LGALS1 and gastric cancer.